» Articles » PMID: 22907121

Cannabis Abuse and Brain Morphology in Schizophrenia: a Review of the Available Evidence

Overview
Specialties Neurology
Psychiatry
Date 2012 Aug 22
PMID 22907121
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Substance abuse is the most prevalent comorbid psychiatric condition associated with schizophrenia, and cannabis is the illicit drug most often abused. Apart from worsening the course of schizophrenia, frequent cannabis use especially at an early age seems to be an important risk factor for developing schizophrenia. Although a large body of neuroimaging studies gives evidence for structural alterations in many different brain regions in schizophrenia patients, there is still limited knowledge of the impact of cannabis abuse on brain structure in schizophrenia. We performed a systematic review including structural magnetic resonance imaging studies comparing high-risk and schizophrenia patients with and without cannabis abuse and found inconclusive results. While there is some evidence that chronic cannabis abuse could alter brain morphology in schizophrenia in patients continuing their cannabis consumption, there is no convincing evidence that this alteration takes place before the onset of schizophrenia when looking at first-episode patients. There is some weak evidence that cannabis abuse could affect brain structures in high-risk subjects, but replication of these studies is needed.

Citing Articles

Magnetic resonance imaging-based machine learning classification of schizophrenia spectrum disorders: a meta-analysis.

Di Camillo F, Grimaldi D, Cattarinussi G, Di Giorgio A, Locatelli C, Khuntia A Psychiatry Clin Neurosci. 2024; 78(12):732-743.

PMID: 39290174 PMC: 11612547. DOI: 10.1111/pcn.13736.


Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response.

Thies M, DeRosse P, Sarpal D, Argyelan M, Fales C, Gallego J Schizophr Bull Open. 2020; 1(1):sgaa014.

PMID: 32803161 PMC: 7418867. DOI: 10.1093/schizbullopen/sgaa014.


Neuroimaging Studies in Patients With Mental Disorder and Co-occurring Substance Use Disorder: Summary of Findings.

Stoychev K Front Psychiatry. 2019; 10:702.

PMID: 31708805 PMC: 6819501. DOI: 10.3389/fpsyt.2019.00702.


Impact of substance use disorder on gray matter volume in schizophrenia.

Quinn M, McHugo M, Armstrong K, Woodward N, Blackford J, Heckers S Psychiatry Res Neuroimaging. 2018; 280:9-14.

PMID: 30121336 PMC: 6815746. DOI: 10.1016/j.pscychresns.2018.08.002.


The adverse health effects and harms related to marijuana use: an overview review.

Memedovich K, Dowsett L, Spackman E, Noseworthy T, Clement F CMAJ Open. 2018; 6(3):E339-E346.

PMID: 30115639 PMC: 6182105. DOI: 10.9778/cmajo.20180023.


References
1.
Haywood T, Kravitz H, Grossman L, Cavanaugh Jr J, Davis J, Lewis D . Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995; 152(6):856-61. DOI: 10.1176/ajp.152.6.856. View

2.
Rasanen P, Tiihonen J, Isohanni M, Rantakallio P, Lehtonen J, Moring J . Schizophrenia, alcohol abuse, and violent behavior: a 26-year followup study of an unselected birth cohort. Schizophr Bull. 1998; 24(3):437-41. DOI: 10.1093/oxfordjournals.schbul.a033338. View

3.
Dekker N, Schmitz N, Peters B, van Amelsvoort T, Linszen D, de Haan L . Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res. 2009; 181(1):51-6. DOI: 10.1016/j.pscychresns.2009.06.003. View

4.
Mathalon D, Pfefferbaum A, Lim K, Rosenbloom M, Sullivan E . Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch Gen Psychiatry. 2003; 60(3):245-52. DOI: 10.1001/archpsyc.60.3.245. View

5.
Szeszko P, Robinson D, Sevy S, Kumra S, Rupp C, Betensky J . Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry. 2007; 190:230-6. DOI: 10.1192/bjp.bp.106.024521. View